Alzheimer's disease (AD) 
Introduction

Alzheimer's disease (AD) has emerged as the most prevalent form (70%) of late-life mental failure in humans, which is characterized by progressive memory deficits, cognitive impairments and personality changes. At gross examination, the Alzheimer's brain shows severe atrophy and a reduction in brain weight of usually more than 35%. The histopathological hallmarks include the presence of extracellular deposition of A␤, neurofibrillary tangles (NFT), progressive synaptic dysfunction and, much later, neuronal death, especially in the hippocampus
.
Most cases of AD are sporadic, while less than 5% of cases are early onset familial Alzheimer's disease (EOFAD; age at onset < 65 years) with an autosomal dominant pattern of inheritance [4] . Among all the known cases of EOFAD, the genetic mutations are found to affect the expression levels of A␤ peptide, which was named amyloid after its starchy appearance following its aggregation. A␤peptide is a 4-kD peptide, 40-43 aa, derived from proteolytic amyloidcleavage of the amyloid precursor protein (APP), which maps to chromosome 21 and is found to be spread on neuronal cells [5] [6] [7] . The [8, 9] . The classical view is that A␤ is deposited extracellularly, however, emerging evidence from transgenic mice and human patients indicates that this peptide can also accumulate intraneuronally, which may contribute to disease progression [10] .
Although A␤ is the major component of the amyloid deposits, other molecules are also associated with these deposits (e.g. ferritin, components of the complement pathway, ␣1-antichymotrypsin, ␣2-macroglobulin, low-density lipoprotein [LDL] receptorrelated protein, APP, acetylcholinesterase, laminin, glycosaminoglycans and the apolipoproteins E and J) [11] [12] [13] . A␤ can adversely affect distinct molecular and cellular pathways, thereby facilitating tau phosphorylation, aggregation, mislocalization and accumulation. Intracellular abnormally phosphorylated tau and A␤ exhibit synergistic effects that finally lead to an acceleration of neurodegenerative mechanisms involved in metabolism, cellular detoxification, mitochondrial dysfunction and energy deficiency, which result in the formation of neuritic plaques [1] . Such plaques are also closely associated with microglia that express surface antigens associated with activation, and surrounded by reactive astrocytes displaying abundant glial filaments. The microglia are usually within and adjacent to the central amyloid core of the neuritic plaque, whereas the astrocytes often ring the outside of the plaque with some of these processes centripetal to the amyloid core [14] (Fig. 1) Fig. 1 ). Among these highly conserved receptors, the most abundant factors expressed on glial cells are the complement receptors [17, 18] , Toll-like receptors (TLRs) and scavenger receptors (SRs) [19] [20] [21] (Table 1) .
The complement system provides an innate immune response against pathogenic features and contributes to the local inflammatory response triggered by A␤ deposition and NFT in AD [17, 22] . The CNS contains components of the complement system that are synthesized by astrocytes, microglia and neurons [17] . Complement component 1q (C1q) has been shown to colocalize with most of the amyloid deposits in brains of AD patients [23] [24] [25] and triggers a complement cascade, including the formation of the membrane attack complex (MAC), C5b-C9 [26] . In brain regions that have dense accumulations of plaques and tangles (e.g. hippocampus and cortex), C1q mRNA level is increased up to 80-fold compared to control levels [27] . Furthermore, the absence of C1q leads to less neuropathology in transgenic mouse models of AD [28] . Therefore, the activation of the classic complement pathway through C1q may provide a specific mechanism for recruiting reactive glial cells to the sites of the A␤ plaque and lead to inflammatory events, neuronal dysfunction and degeneration through production of pro-inflammatory cytokines and oxidative products such as nitric oxide [22, 29] [190, 191] MHC-II + + [62, 192] Mannose receptor: [193] The Transforming growth factor ␤ (TGF-␤) is a cytokine with neuroprotective features that can be released by both neurons and glia in response to stress [43] . Brain TGF-␤1 is increased in AD brains compared with controls and positively correlates with the extent of cerebrovascular brain amyloid deposition and cerebral amyloid angiopathy (CAA) [44] . Interestingly, coexpression of TGF-␤1 with hAPP/A␤ in bigenic mice resulted in reduction of brain A␤ while elevating cerebrovascular and meningeal amyloid deposition at 2-3 months of age [45] .
Microglia
Activated microglia represent the major source of inflammatory factors in the brain in neurodegenera-
tive disorders such as AD [46] . In AD, activated microglia diffusely situate throughout the cerebral cortex, and focally concentrate in A␤ plaques [47] . Microglia accumulate in plaques containing A␤ fibrils, but not in plaques containing amorphous non-fibrillar amyloid [47] [49, 50] .
An accumulation of damaged neuronal DNA fragments can be potent promoters of microglial activation in AD [51] . Activated microglia were found to contain fragmental DNA (fDNA) in their cytoplasm (AD brains and in culture) [51] . Furthermore, A␤ fibril interacts with numerous microglial membrane receptors including scavenger receptor A (SRA) [20, 52] and B [20] , CD36 [53] , CD40 [54] , ␣6/␤1 integrin-CD36-CD47 complex [55] and complement receptors [56] (Table 1) . Soluble A␤ can be directly bound by microglial cell receptors, including the heparan sulphate proteoglycans (HSPGs) [57] , insulin receptors [58] , proteinase inhibitor (serpin)-enzyme complex receptor (SEC-R) [59] and an accumulation of the receptor for advanced glycation end products (RAGE) [60, 61] . [62] . [62] [63] [64] .
Activated microglia bearing major histocompatibility complex (MHC) type II antigens on their surface are associated with A␤ fibrils in AD brain samples, and may interact with infiltrated T cells to induce inflammation as observed in autoimmune diseases
Isolated microglia from postmortem AD and control (non-demented) patients' brain tissue exhibit pro-inflammatory cytokine expression profiles, in the form of a significantly increased expression of IL-1␤, TNF-␣, IL-6 and IL-12, following an exposure to A␤ peptides. These results strongly suggest that either the A␤ peptides or the plaques can initiate the activation of microglia and subsequent release of proinflammatory molecules in the AD brain
The possible function of the activated microglia may be scavenger cells, since they represent macrophagederived cells in the CNS and therefore are capable of rapidly responding to the accumulation of foreign material, such as A␤ deposits [47] (Table 1) . A defi-ciency in the activation of microglia in transgenic mouse models of AD promotes A␤ deposition and increases mortality in these mice [65] . Furthermore, a recent study reports that microglial cells exhibit significant telomere shortening and a reduction of telomerase activity in normal aging rats [66] , and that in humans there is a tendency toward microglial cell telomere shortening with a presence of dementia [66] . Human brains containing high-amyloid loads demonstrate a significantly higher degree of microglial dystrophy than non-demented, amyloid-free control subjects [66] . This suggests that degeneration of microglia is a factor in the pathogenesis of AD [47] .
Neurons can influence microglial functions, through direct cell-to-cell interactions as well as with the release of soluble mediators, such as neurotransmitters [67] . A recent article describes the up-regulation of nicotinic acetylcholine receptor ␣7 in cholinergic basal forebrain neurons in AD [68] . This receptor is also expressed by microglial cells and its activation weakens the pro-inflammatory response of microglial cultures, suggesting that acetylcholine may control brain inflammation [68] .
Microglial cell activation can target A␤ plaques in the brain using many different mechanisms, and the source of the microglial cells can be brain resident or bone marrow-derived microglial cells [69] . [70] . Neuropathological studies have found MCP-1 [71] and an increased expression of the chemokine receptors CCR3 and CCR5 in reactive microglia [72] . Recent [77, 78] . Astrocyte activation seems to be particularly prominent around A␤ deposits both in the brain parenchyma and in the cerebrovasculature [63] . Astrocyte activity is marked by hypertrophy [79] , resulting in an expression of proteins such as glial fibrillary acidic protein (GFAP), S100B [78, 80] , adhesion molecules and antigen presenting capabilities, including MHC antigens [81, 82] . Tissue levels of S100B correlates with the number of neuritic plaques in the temporal lobe [78, 83] [85] and IL-12 [85] . Furthermore, an astrocytic response to IL-1␤ and TNF-␣ results in an elevation of colony stimulating factor 1 (CSF-1) [86] , granulocyte-macrophage CSF (GM-CSF) [86] , granulocyte CSF (G-CSF) [86] , MCP-1 and MIP-1␣ [33, 87] , which can lead to the recruitment of microglial cells to A␤ plaques [88] . The CXCL10 ligand for CXCR3 can be present in subpopulations of astrocytes associated with senile plaques in AD brains compared with controls [89] .
Microglia cultured from rapid autopsies of AD and non-demented patients reveal an increased expression of chemokines such as IL-8, monocyte chemoattractant protein-1 (MCP-1; also known as CCL2) and macrophage inflammatory MIP-1␣ (CCL3) after experimental exposure to A␤
In AD, activated astrocytes can contain A␤ fragments, providing further evidence of their role in A␤ degradation [90] . Furthermore, Wyss-Coray et al. [91] [92] . The isoform apolipoprotein E4 (APOE4) is a risk factor for developing AD at an earlier age and might contribute to this effect [92] . The putative clearance mechanism of A␤ by astrocyte may depend on their expression of APOE3 [93] . Furthermore, high expression of APOE4 in astrocytes can reduce their response to A␤ deposits [94, 95] . Thus, APOE3 seems to be important in the degradation and clearance of deposited A␤ species by astrocytes, a process that may be impaired in AD [93] . Fig. 2 ) [97] [98] [99] . LRP-1 and RAGE perform opposite functions in transporting A␤ [97] ; RAGE transports A␤ into the brain and LRP transports A␤ out of the brain.
Glial cells mediate the peripheral immune response in AD
-␤ (TGF-␤); tumour necrosis factor-␣ (TNF-␣); interleukins and chemokines. TGF-␤1 potentiates A␤ production in human astrocytes and thus favouring continuing deposition of A␤, which in turn activates glial cell synthesis and the release of a number of cytokines. Low-density lipoprotein (LDL) receptor-related protein (LRP-1) and receptor for advanced glycation end products (RAGE) perform opposite functions in transporting A␤. The weakening of the vessel wall is the likely cause of intracerebral haemorrhage.
Glial cell interaction with endothelial cells
LRP plays an important role in the balance between A␤ synthesis and clearance mechanisms [99] . LRP is expressed in reactive astrocytes and in the brain capillary endothelium [99, 100] [102] . The protective effect was greater for ApoE3 than for ApoE4, the expression of which is a risk factor for AD [103] [104, 105] . [97] . [106] . Severe AD is associated with significant changes in the relative distribution of RAGE and LRP-1 in the human hippocampus, as compared with age-matched controls [100] . [43] . Overexpression of TGF-␤1 by the promoter of the GFAP, a specific marker of astrocytes, within the CNS can result in cerebrovascular amyloid and enhance immune cell infiltration from peripherally triggered autoimmune responses [107] (Fig. 2) . In AD, the deposition of amyloid around cerebral blood vessels can lead to CAA which occurs in 80% of AD cases [108] . A␤ deposits in the cerebrovasculature are associated with the alteration of smooth muscle cells [109] , the thinning of endothelial cells [110] and the loss of endothelial mitochondria [110] . The deposits cause intraparenchymal and subarachnoid bleeding, which leads to haemorrhage, stroke with hemosiderin deposits, multiple infarcts and cognitive impairment [109] (Fig. 2) . A␤ increases endothelial monolayer permeability [111, 112] , stimulates secretion of inflammatory cytokines [113] and up-regulates vascular cell adhesion molecules (Fig. 2) . [114] . In the human trial of A␤-peptide vaccination in which meningoencephalitis followed immunization with A␤ peptide [115, 116] [117] . [118] . Transgenic mice overproducing A␤, but deficient in CD40L, show reduced A␤ levels and A␤ plaque load [118] . This finding suggests several possible mechanisms underlying mitigation of AD pathology in response to CD40L and validates the CD40-CD40L interaction as a target for therapeutic intervention in AD [54, 118] [119] [120] [121] .
. Glial cells secrete the LRP ligand, ApoE-containing lipoproteins (ApoE-LPs) [101], which have an important role in lipid homeostasis in the CNS. Glia-derived APOELPs also promote synaptogenesis and stimulate axon growth of CNS neurons [101]. In addition, binding APOE-LPs to LRP initiates the prevention of neuronal apoptosis
. ApoE3 might be involved in the up-regulation of LRP and increase clearance of A␤ from the brain [103] (Table 1). These findings support the hypothesis that glial cells may play an important role in mediating A␤ transport through the endothelial cells. RAGE is a multi-ligand receptor of the immunoglobulin super family of cell surface molecules and is expressed on endothelial and glial cells
RAGE is implicated in the development of the Alzheimer's neurovascular disorder by mediating circulating A␤ transcytosis across the BBB. After BBB transport, the circulating A␤ is rapidly taken up by neurons thereby inducing cellular stress. Hence, the RAGE-A␤ interaction in brain endothelium leads to an expansion of endothelin-1, a potent vasoconstrictor, resulting in a suppression of blood flow
Dysfunction in the BBB clearance of A␤ through deregulated LRP1/RAGE-mediated transport, aberrant angiogenesis and arterial dysfunction may initiate neurovascular uncoupling, A␤ accumulation, cerebrovascular regression, brain hypoperfusion and neurovascular inflammation
TGF-␤1 is a multi-functional cytokine that is a major regulator of the immune response and has profound affects on vasculogenesis, angiogenesis and the maintenance of vessel wall integrity
Glial cell interaction with T cells
Although there is no clear T-cell response in the brains of AD patients, understanding T-cell responses and adaptive immunity has become important in AD immunotherapy. Studies show a stronger T-cell response to A␤, in a proportion of healthy elderly individuals and patients with AD, than in middle-aged adults
T cells. Recent works suggest that the final maturation of T cells might occur in the CNS through an interaction with resident antigen presented cells. Therefore, glial cells have an important role in facilitating the response to T cells. The glial cell-T cell interaction occurs through different receptors and the first type of signal mediates the fate of the immune response
Different types of T cells would be expected to have different effects on microglial cell activation and therefore on amyloid clearance. Th1 cells can promote microglial cell activation through the secretion of IFN-␥, which also up-regulates the expression of MHC class II molecules by microglial cells, thereby enhancing the T cell-microglial cell interaction. Recent evidence has shown that the interaction of CD40 (expressed on the surface of microglia) with CD40L (T-cell receptor) promotes pro-inflammatory microglial cell activation in response to A␤
(Table 1). As part of the defence mechanism of preventing brain inflammation, glial cells can facilitate apoptosis of the infiltrating T cells through signalling pathways initiated by CD95L, CD95L (FasL)/CD95 (Fas), perforin and the TNF receptor 1 (TNFR1) pathway
T [65, 117, 122, 123] (Table 1) .
-cell responses might also be beneficial by aiding the clearance of A␤, most likely through the activation of microglial cells. Hence, understanding the interaction between glial cells and T cells may reveal a new target for modulating brain inflammation and help in developing novel immunotherapeutic approaches to AD.
Glial cell activation as therapeutic target in AD
Glial cells provide a natural mechanism by which protein aggregates (including amyloid) and debris can be removed from the brain. In addition to their innate ability to phagocytose and clear A␤, glial cells can also be activated to promote the clearance of A␤ and prevent neuronal death in AD
Epidemiological studies have documented a reduced prevalence of AD among users of nonsteroidal anti-inflammatory drugs (NSAIDs) [124, 125] . The main known target of NSAIDs are the cyclooxygenase (COX) enzymes [125] . However, studies by Weggen et al . [126] demonstrate that a subset of NSAIDs lower amyloidogenic A␤ independently of COX activity and appear to operate by decreasing the activity of ␥-secretase, an enzyme linked to increased production of A␤. These findings support the view that decreasing the inflammatory response is not necessarily beneficial in AD and may not be linked to a reduction of A␤ in the brain. In support of this, Jantzen and colleagues [127] [117, 128, 129] , which is characterized by an extension of pseudopodia and an envelopment of the phagocytic target by a mechanism of tyrosine kinases, Rac and Cdc42 [130] . Active immunization with A␤ in mouse models of AD [131] , and immunotherapy by passive administration of amyloid-specific antibodies [132] induce microglial cell activation and markedly reduces amyloid levels in the brain and reverses behavioural impairment in these mice [133, 134] . Furthermore, restricting A␤-specific antibodies with anti-inflammatory drugs, such as dexamethasone, reduces microglial cell activation and inhibits the removal of fibrillar amyloid deposits [135] . There is also evidence that intravenous immunoglobulin (IVIg), an FDA-approved purified immunoglobulin fraction from normal human donor blood, shows promise as a passive immunotherapy for AD, which enhances microglial cell migration toward A␤ deposits, and mediates phagocytosis of A␤ [136] .
The first human clinical trial of immunizing AD patients with A␤ peptide led to the activation of T cells and meningoencephalitis in some patients so the trial was discontinued [115] . Nevertheless, the cases of meningoencephalitis did not correlate with the presence of highly elevated concentrations of antibody titres to A␤, and it is now generally believed that the meningoencephalitis was due to a T-cell response against A␤ resulting from the type of adjuvant that was used [117] . Furthermore [143, 144] [146] . APP mouse models with TLR4 deficiency have an increase in insoluble A␤ in the cortex, as compared to TLR4 wild-type APP mouse models [146] . The activation of microglia with a TLR2, TLR4 or TLR9 ligand markedly boosted the ingestion of A␤ in vitro [146] . These results suggest that the TLR signalling pathways may be involved in the clearance of A␤ deposits in the brain and that TLRs can be a therapeutic target for application in AD [146] . [149] . This suggests that a lactadherin deficiency significantly limits A␤ phagocytosis. Hence, alterations in lactadherin production or function may contribute to the initiation or progression of AD [149] .
Complement components may modulate the phagocytosis of A␤ by microglia [150] . Moreover [155] [156] [157] . In these studies, LPS was given intravenously [155] , intracerebroventricularly [156] or intraperitoneally [157] . However, others studies showed enhanced A␤ clearance through microglial cell activation when LPS was injected intrahippocampally [158, 159] or intracranial [160] [166, 167] . NAP is currently in phase II clinical trials by Allon Therapeutics to assess the affects on MCI [162] .
Adult hippocampal neurogenesis, the process that creates neurons, dramatically decreases with increasing age and it has been proposed that this decline may contribute to age-related memory deficits, such as in AD [168, 169] [170] . Recent works suggest that glial cells can mediate neurogenesis in neurodegenerative diseases, such as AD [144] . 
Conclusion
